secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-09-17T23:59:59+00:00
Accession:  0001104659-24-100709
Event type: regulatory
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 5.03, 5.07, 5.08, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma approves 1-for-25 reverse stock split, regains Nasdaq equity compliance
--------------------------------------------------------------------------------

- Board approved 1-for-25 reverse split; effective Sept 20, trading split-adjusted Sept 23.
- Authorized shares increased from 125M to 250M; stockholders approved conversion of Series C Preferred.
- Director James Marino resigned; Luba Greenwood appointed to board and committees.
- Company believes it now satisfies Nasdaq $2.5M stockholders' equity requirement after conversion; delisting risk remains.
- Annual meeting set for Oct 31, 2024; shareholder proposals due Sept 26, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/0001104659-24-100709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924100709/tm2424247d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-100709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer